Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
Preprint
- 19 July 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals were of low neutralizing titer (IC50 <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest the benefit of a second immunization following Ad26.COV2.S to increase protection against the variants.Keywords
Other Versions
- Published version: Version Frontiers in Immunology, 13, preprints
This publication has 21 references indexed in Scilit:
- Serum Neutralizing Activity Elicited by mRNA-1273 VaccineThe New England Journal of Medicine, 2021
- Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacitiesScientific Reports, 2021
- Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodiesPublished by Cold Spring Harbor Laboratory ,2021
- The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2Proceedings of the National Academy of Sciences of the United States of America, 2021
- Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited seraNature Medicine, 2021
- Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodiesPublished by Cold Spring Harbor Laboratory ,2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2Cell Reports, 2020
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacyScience, 2020
- Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 BindingCell, 2020